Severe Acute Respiratory Syndrome Coronavirus 2 Seroprevalence Among Adults in a Tropical City of the Caribbean Area, Colombia: Are We Much Closer to Herd Immunity Than Developed Countries?

Mattar, Salim; Alvis‐Guzmán, Nelson; Garay, Evelin; Rivero, Ricardo; García, Alejandra; Botero, Yesica; Miranda, Jorge; Galeano, Ketty; Hoz, Fernando de la; Martínez, Caty; Arrieta, Germán; Faccini-Martínez, Álvaro A.; Guzmán, Camilo; Kerguelen, Hugo; Moscote, Maria; Contreras, Héctor; Contreras, Verónica

doi:10.1093/ofid/ofaa550

Cited by 20 publications

(21 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Depending on vaccine coverage and effectiveness against infectiousness with future circulating variants – which may be antigenically dissimilar to B.1.1.7 [ 8 ] – herd immunity to SARS-CoV-2 in the absence of other non-pharmaceutical interventions may not be reached until considerable natural immunity has accumulated. As some countries now have a sizeable subpopulation with protective antibodies acquired through natural infection [ 9 ], we estimated the probability of reaching the HIT for SARS-CoV-2 under varying degrees of vaccination coverage against a background of reduction in transmission from natural immunity.…”

Section: Covid-19 Vaccination Coverage Needed Considering Natural Immunitymentioning

confidence: 99%

“…If the B.1.1.7 variant dominates, countries with a high proportion of adults require much higher effectiveness, ca 90%, to reach the HIT after an adult immunisation campaign, and many countries with a lower adult population proportion are again unlikely to reach the HIT through vaccination. Although there are some regional and local studies in countries such as Brazil [ 14 ], Italy [ 15 ], and Columbia [ 9 ] showing high seroprevalence at the local level, much lower seroprevalence has been estimated at the national level. For countries in which there is substantial heterogeneity in natural immunity, these estimates for herd immunity are unlikely to equate to a pragmatic protective threshold.…”

Section: Controlling Sars-cov-2 Spread In Populations With Different Age Structure and Seroprevalencementioning

confidence: 99%

See 1 more Smart Citation

The potential for vaccination-induced herd immunity against the SARS-CoV-2 B.1.1.7 variant

2021

View full text Add to dashboard Cite

We assess the feasibility of reaching the herd immunity threshold against SARS-CoV-2 through vaccination, considering vaccine effectiveness (VE), transmissibility of the virus and the level of pre-existing immunity in populations, as well as their age structure. If highly transmissible variants of concern become dominant in areas with low levels of naturally-acquired immunity and/or in populations with large proportions of < 15 year-olds, control of infection without non-pharmaceutical interventions may only be possible with a VE ≥ 80%, and coverage extended to children.

show abstract

Section: Covid-19 Vaccination Coverage Needed Considering Natural Immunitymentioning

confidence: 99%

Section: Controlling Sars-cov-2 Spread In Populations With Different Age Structure and Seroprevalencementioning

confidence: 99%

The potential for vaccination-induced herd immunity against the SARS-CoV-2 B.1.1.7 variant

2021

View full text Add to dashboard Cite

show abstract

“…Local studies have been realized in Monteria and Bogotá. In Montería, 1368 individuals were randomly selected from the population, and between July and August 2020, a seroprevalence of 55.3% was estimated [ 26 ]; this was one of the highest seroprevalences in Colombia and Latin America for the time. A few small occupational studies have also been conducted.…”

Section: Discussionmentioning

confidence: 99%

Seroprevalence of SARS-CoV-2 Infection among Occupational Groups from the Bucaramanga Metropolitan Area, Colombia

Colmenares-Mejía

Díaz

Quintero-Lesmes

et al. 2021

IJERPH

View full text Add to dashboard Cite

The negative effects of coronavirus disease 2019 (COVID-19) pandemic have impacted the world economy due to the absence from work because of SARS-CoV-2 infection in workers, among other reasons. However, some economic areas are essential to society and people must continue working outside the home to support economic reactivation; their serological profile could be different from that of the global population. Cross-sectional study: Workers from health, construction, public transportation, public force, bike delivery messengers, independent or informal commerce areas, and residents of Bucaramanga or its metropolitan area were invited to participate. All participants self-completed a virtual survey and a blood test was taken to assess IgG and IgM with the ARC COV2 test. Seroprevalence was estimated considering a complex survey design, correcting for a finite population effect and adjusting for test performance. A total of 7045 workers were enrolled; 59.9% were women and most were residents of Bucaramanga and working in health occupations. The global adjusted seroprevalence was 19.5% (CI: 95% 18.6–20.4), being higher for Girón (27.9%; 95% CI: 24.5–31.30). Workers with multiple contact with people during working hours or using public transportation to go to work had a higher frequency of seropositivity for SARS-CoV-2. The seroprevalence among workers living in these four municipalities from the Colombian northeast area is still low.

show abstract

“…In the national seroprevalence survey done by the Colombian National Institute of health (INS), crude and adjusted seroprevalence for Bogotá during October and November 2020 among 4,597 individuals was 26.3% and 30% a, respectively (19). Higher seroprevalence has been described for cities in the Caribbean area of Colombia reaching up to 55.3% (20). In a study carried in a university hospital in Bogotá during the first peak showed a baseline seroprevalence of 2.28% among health workers, increasing to 5.98% after 2-4 weeks of follow; with 38% of individual being pre-symptomatic or asymptomatic (21).…”

Section: Discussionmentioning

confidence: 99%

Seroreactivity to SARS-CoV-2 in individuals attending a university campus in Bogotá Colombia

González

Santos-Barbosa

Jaller

et al. 2021

Preprint

View full text Add to dashboard Cite

Most community-specific serological surveys for SARS-CoV-2 antibodies have been done in healthcare workers and institutions. In this study, IgG antibodies specific for the virus were evaluated in individuals working at one university in Bogota-Colombia. The aim of this work was to determine previous exposure to SARS-CoV-2 in those attending the campus during city lockdown. A total of 237 individuals including 93 women and 144 men were evaluated using chemiluminescent detection of IgG anti N-viral protein. There were 32 positives giving a seroprevalence of 13.5% (10 women and 22 men) and mostly asymptomatic (68.75%). Only 13 of the seropositive individuals had previous positive detection of SARS-CoV-2 RNA by RT-qPCR done in average 91 days before serological test. Seropositive individuals did not come from localities having higher percentages of SARS-CoV-2 cases in the city. Three cluster of seropositive individuals were identified. This survey was carried out after the first peak of SARS-CoV-2 transmission in the city, and before the preparedness to reopening the campus for students in 2021. These results will help to develop some of the strategies stablished to control virus spread in the campus.

show abstract

Severe Acute Respiratory Syndrome Coronavirus 2 Seroprevalence Among Adults in a Tropical City of the Caribbean Area, Colombia: Are We Much Closer to Herd Immunity Than Developed Countries?

Cited by 20 publications

References 9 publications

The potential for vaccination-induced herd immunity against the SARS-CoV-2 B.1.1.7 variant

The potential for vaccination-induced herd immunity against the SARS-CoV-2 B.1.1.7 variant

Seroprevalence of SARS-CoV-2 Infection among Occupational Groups from the Bucaramanga Metropolitan Area, Colombia

Seroreactivity to SARS-CoV-2 in individuals attending a university campus in Bogotá Colombia

Contact Info

Product

Resources

About